Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy
Nicola Maurea(Cancer Institute (WIA)), Rosario Vincenzo Iaffaioli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmela Coppola, G. Frasci(Radiation Oncology Institute), Gianluca Ragone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmela Romano(Centro di Riferimento Oncologico della Basilicata), Annamaria Bonelli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 49
Related Papers
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis
|Annals of Oncology|2009|205
Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer: Interim Analysis of a Phase III Trial of the Southern Italy Cooperative Oncology Group
|Journal of Clinical Oncology|2000|177
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116